Salicylate inhibits phosphorylation of the nonreceptor tyrosine kinases, proline-rich tyrosine kinase 2 and c-Src

Hypertension

Volumn 37, Issue 1, 2001, Pages 148-153

  Wang, Zhongyan ^a   Brecher, Peter ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblasts; Kinase; NSAIDs; Signal transduction

Indexed keywords

ANGIOTENSIN; CALCIMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHORBOL ESTER; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR; PROLINE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SALICYLIC ACID; THAPSIGARGIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CHELATION; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; FIBROBLAST; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; ONCOGENE SRC; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0035156438     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.37.1.148     Document Type: Article

References (25)

1. Inhibition of neutrophil function by aspirin-like drugs (NSAIDS): Requirement for assembly of heterotrimeric G proteins in bilayer phospholipid
2. Modes of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin-dependent neutrophil adhesion
3. Sulindac inhibits activation of the NF-kappaB pathway
4. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
5. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
6. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts
7. Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts
8. Salicylate inhibition of extracellular signal-regulated kinases and inducible nitric oxide synthase
9. Nitric oxide and N-acetylcysteine inhibit the activation of mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts
10. Nitric oxide inhibits angiotensin II-induced activation of the calcium-sensitive tyrosine kinase proline-rich tyrosine kinase 2 without affecting epidermal growth factor receptor transactivation
11. Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca(2+) levels
12. Angiotensin II signal transduction in vascular smooth muscle: Pathways activated by specific tyrosine kinases
13. Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells
14. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation
15. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells
16. Matsubara H. Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor
17. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor: Dependence on calcium and the actin cytoskeleton
18. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle
19. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells
20. Expression and characterization of splice variants of PYK2, a focal adhesion kinase-related protein
21. Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions
22. Signal transduction via platelet-derived growth factor receptors
23. NSAID's: Aspirin and aspirin-like drugs
24. Analgesic-antipyretics and antiinflammatory agents: Drugs employed in the treatment of rheumatoid arthritis and gout
25. Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals